Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |||||
---|---|---|---|---|---|---|---|---|---|
Protein | P value | Protein | P value | Protein | P value | Protein | P value | Protein | P value |
LXR/RXR activation | 2.04E−12 | Glycolysis I | 2.06E−07 | LXR/RXR activation | 3.14E−15 | LXR/RXR activation | 3.11E−18 | LXR/RXR activation | 2.92E−19 |
Glycolysis I | 3.13E−11 | LXR/RXR activation | 1.02E−04 | FXR/RXR activation | 1.69E−13 | Acute phase response signaling | 5.67E−16 | FXR/RXR activation | 2.88E−17 |
FXR/RXR activation | 8.01E−10 | Clathrin-mediated endocytosis signaling | 6.79E−04 | Acute phase response signaling | 2.32E−09 | FXR/RXR activation | 7.25E−15 | Acute phase response signaling | 1.53E−15 |
Gluconeogenesis I | 1.61E−09 | Gluconeogenesis I | 1.25E−03 | Atherosclerosis signaling | 2.97E−09 | Glycolysis I | 1.24E−11 | Clathrin-mediated endocytosis signaling | 5.04E−09 |
Acute phase response signaling | 2.36E−09 | FXR/RXR activation | 2.08E−03 | Clathrin-mediated endocytosis signaling | 1.06E−08 | Atherosclerosis signaling | 3.63E−09 | Glycolysis I | 1.01E−08 |